Bromelains is a Enzyme owned by MediWound, and is involved in 15 clinical trials, of which 13 were completed, and 2 are ongoing.
Bromelain is a debridement agent which contains mixture of enzymes that digest protein. The drug candidate has fibrinolytic and proteolytic activity by which it facilitates the reabsorption of hematic effusions. The proteolytic enzymes present in the drug candidate act by dissolving the burn wound eschar (dead and damaged tissues) without harming the healthy tissues which may prove to be effective in treating the disease condition.
The revenue for Bromelains is expected to reach a total of $250m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Bromelains NPV Report.
Bromelains (NexoBrid) is a protein extract derived from the stems of Pineapples, Ananas comosus. It is formulated as powder and gel for cutaneous route of administration. It is indicated for removal of eschar in adults with deep partial and full-thickness thermal burns.
The drug candidate is under development for the treatment of severe burns, sulfur mustard (chemical warfare agent) injuries in the U.S., EU, Japan and India. The development of the drug candidate is based on proteolytic enzymatic technology.
MediWound is a biopharmaceutical company that develops, manufactures and markets novel therapeutics to address the unmet needs in the areas of chronic, severe burns, other hard-to-heal wounds and for connective tissue disorders. The company uses its patented proteolytic enzyme technology for the development of its products. The company offers NexoBrid, a drug for the removal of damaged or dead tissue, namely, eschar, in adults with severe burns (deep partial and full-thickness thermal burns). EscharEX, pipeline drug candidate for the removal of damaged, dead or infected tissues from chronic wounds; MWPC003, a pre-clinical candidate for treating connective tissue Disorders. The company markets NexoBrid in the Europe and Israel through its own commercial organization and in Russia, Peru, India, Bangladesh, South Korea, Argentina through distributors. MediWound is headquartered in Yavne, Israel.
The company reported revenues of (US Dollars) US$23.8 million for the fiscal year ended December 2021 (FY2021), an increase of 9.2% over FY2020. The operating loss of the company was US$11.2 million in FY2021, compared to an operating loss of US$8.8 million in FY2020. The net loss of the company was US$13.6 million in FY2021, compared to a net loss of US$9.2 million in FY2020. The company reported revenues of US$5.8 million for the third quarter ended September 2022, an increase of 24.3% over the previous quarter.
Quick View – Bromelains
|Highest Development Stage|